Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | BMP2 | P12643 | 1/20 | 0.30 |
| ▸ | VEGFA | P15692 | 1/20 | 0.30 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.30 |
| ▸ | SHH | Q15465 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11997512 | 0.89 | F10 (0.39) | F10 | |
| SCHEMBL11921946 | 0.87 | F10 (0.38) | F10 | |
| SCHEMBL11921943 | 0.81 | F10 (0.38) | F10BMP2VEGFACXCL12SHH | |
| SCHEMBL11921864 | 0.81 | FGF1 (0.35) | F10VEGFA | |
| SCHEMBL11921947 | 0.78 | F10 (0.39) | F10 | |
| SCHEMBL11921952 | 0.76 | F10 (0.42) | F10 | |
| SCHEMBL11997499 | 0.74 | F10 (0.40) | F10BMP2VEGFACXCL12SHH | |
| SCHEMBL11921953 | 0.74 | F10 (0.41) | F10 | |
| SCHEMBL11921951 | 0.74 | F10 (0.41) | F10 | |
| SCHEMBL11921949 | 0.74 | F10 (0.41) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527930-B2 | FGF receptor-activating N-sulfate oligosaccharides, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2016-12-27 | — | — | US | disclosed |
| US-20120202769-A1 | FGF RECEPTOR-ACTIVATING N-SULFATE OLIGOSACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202769-A1 | FGF RECEPTOR-ACTIVATING N-SULFATE OLIGOSACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | FGFR1, FGF1, FGF2 | F10 225/4885BMP2 118/4885VEGFA 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.